Catalyst Event
Lululemon Athletica Inc (LULU) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/18/2026, 12:00:00 AM
Founder Chip Wilson publicly criticized the board and Q4 2025 results on 2026-03-18, citing declining Americas sales and a weak 2026 outlook, and is running a proxy campaign for new directors. Medium importance is assigned as this governance conflict is estimated by analysts to cause a >5% price impact; scheduled.
Korean Translation
창업주 칩 윌슨이 2026-03-18에 미주 매출 정체와 부진한 전망을 이유로 이사회를 비판하며 새로운 이사 선임을 위한 위임장 대결을 시작함. 이러한 경영권 분쟁은 5% 이상의 주가 변동을 초래할 것으로 분석가들에 의해 예상되며, 해당 캠페인은 예정됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
The ex-dividend date for the quarterly cash dividend of $1.25 per share is March 27, 2026, representing a 3% increase over the previous quarterly dividend.
3/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Annual General Meeting 2026 scheduled.
3/26/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
HSBC downgraded the stock from 'Hold' to 'Reduce' with a price target of $850, citing valuation concerns and competitive pressures.
3/22/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Patents for semaglutide, the active ingredient in Ozempic and Wegovy, expired in key markets including China and India. This event opens the door to generic competition in those regions.
3/20/2026, 12:00:00 AM